Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?

Thrill-seeking investors can get their fill with the rollercoaster rides provided by clinical-stage biotech stocks. Just look at Summit Therapeutics (NASDAQ: SMMT).By May 7, 2024, Summit Therapeutics stock had more than doubled year to date. Only three weeks later, the biopharmaceutical company's share price was down 8% year to date -- a huge swing in the wrong direction.However, investors who threw in the towel then are no doubt kicking themselves now. Summit Therapeutics stock has delivered a gain of nearly 10x in 2024 after skyrocketing over the last few months. Is it too late to buy this high-flying biotech stock?Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool